Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 27Parkinson Disease 4, Autosomal Dominant Lewy Body 24Neoplasms 14Melanoma 9Endometrial Neoplasms 8Carcinoma, Renal Cell 7Carcinoma, Non-Small-Cell Lung 7Thyroid Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Cholangiocarcinoma 6Stomach Neoplasms 4Recurrence 4Carcinoma 4Biliary Tract Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Paraganglioma, Extra-Adrenal 2Osteosarcoma 2Neuroendocrine Tumors 2Lung Neoplasms 2Liver Neoplasms 2Glioma 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid cancer, Hurthle cell 1

Interventions

tislelizumab 1lenvatinib 1Radiomics 1Positron Emission Tomography Computed Tomography 1Pancreaticoduodenectomy 1Electroporation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pancreatic Ductal Adenocarcinoma × lenvatinib × Clear all
NCT05303090 2025-02-27

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Fudan University

Phase 1 Completed
56 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡